Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver.

OBJECTIVE The purpose of this study was to compare, with histopathologic examination of the liver explant as the reference standard, diffusion-weighted MRI with contrast-enhanced subtraction MRI in the assessment of necrosis of hepatocellular carcinoma (HCC) after trans arterial chemoembolization (TACE). MATERIALS AND METHODS The cases of 21 patients with HCC who underwent MRI after TACE were evaluated. Two independent observers calculated the apparent diffusion coefficient (ADC) of HCC and measured percentage tumor necrosis on subtraction images. The ADCs of necrotic and viable tumor tissues were compared. ADC and percentage necrosis on subtraction images were correlated with percentage necrosis found at pathologic examination. Receiver operating characteristics analysis was performed on the diagnosis of complete tumor necrosis. RESULTS Twenty-eight HCCs (mean diameter, 2.3 cm) were evaluated. There were significant differences between the ADC of viable tissue and that of necrotic tumor tissue (1.33 +/- 0.41 vs 2.04 +/- 0.38 x 10(-3) mm(2)/s, p < 0.0001). There was significant moderate correlation between ADC and the pathologic finding of percentage necrosis (r = 0.64, p < 0.001) and significant strong correlation between subtraction image and pathologic percentage necrosis (r = 0.89-0.91, depending on the phase; p < 0.001). In the diagnosis of complete tumor necrosis, ADC had an area under the curve, sensitivity, and specificity of 0.85, 75%, and 87.5% compared with 0.82-0.89, 100%, and 58.3-79.1% for subtraction imaging (p > 0.5 between ADC and subtraction imaging). CONCLUSION Compared with diffusion-weighted imaging, contrast-enhanced MRI with subtraction technique had more significant correlation with the histopathologic findings in the evaluation of necrosis of HCC after TACE. There was no difference, however, between the two methods in diagnosis of complete tumor necrosis.

[1]  B. Taouli,et al.  Diffusion and perfusion imaging of the liver. , 2010, European journal of radiology.

[2]  H. Jaeger,et al.  Sequential transarterial chemoembolization for unresectable advanced hepatocellular carcinoma , 1996, CardioVascular and Interventional Radiology.

[3]  R. Sinkus,et al.  Imagerie de diffusion hépatique , 2010 .

[4]  J K Boitnott,et al.  Local tumor recurrence following hepatic cryoablation: radiologic-histopathologic correlation in a rabbit model. , 2000, Radiology.

[5]  V. Mazzaferro,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.

[6]  B. Kiefer,et al.  Diagnosis of hepatic metastasis: comparison of respiration-triggered diffusion-weighted echo-planar MRI and five t2-weighted turbo spin-echo sequences. , 2008, AJR. American journal of roentgenology.

[7]  Ning-Yu An,et al.  Differentiation of clinically benign and malignant breast lesions using diffusion‐weighted imaging , 2002, Journal of magnetic resonance imaging : JMRI.

[8]  David A Bluemke,et al.  Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. , 2009, Radiology.

[9]  B. Siewert,et al.  Abdominal diffusion mapping with use of a whole-body echo-planar system. , 1994, Radiology.

[10]  Ramon Planas,et al.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial , 2002, The Lancet.

[11]  R C McKinstry,et al.  Evaluating pediatric brain tumor cellularity with diffusion-tensor imaging. , 2001, AJR. American journal of roentgenology.

[12]  P. Torricelli,et al.  MRI of Hepatocellular Carcinoma before and after Transcatheter Chemoembolization , 1993, Journal of computer assisted tomography.

[13]  A. Djamali,et al.  Nephrogenic systemic fibrosis: risk factors and incidence estimation. , 2007, Radiology.

[14]  B K Rutt,et al.  Quantitative diffusion imaging in implanted human breast tumors , 1997, Magnetic resonance in medicine.

[15]  S. Nawano,et al.  Hepatic metastases: diffusion-weighted sensitivity-encoding versus SPIO-enhanced MR imaging. , 2006, Radiology.

[16]  Jo-Chi Jao,et al.  Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: choline levels and MR diffusion constants--initial experience. , 2006, Radiology.

[17]  B. Taouli,et al.  Diffusion-weighted MR imaging of the liver. , 2010, Radiology.

[18]  T. Grobner.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  H. Schild,et al.  Abdomen: diffusion-weighted MR imaging with pulse-triggered single-shot sequences. , 2002, Radiology.

[20]  Y. Jeong,et al.  Imaging features of hepatocellular carcinoma after transcatheter arterial chemoembolization and radiofrequency ablation. , 2006, AJR. American journal of roentgenology.

[21]  H. Thomsen,et al.  Update on nephrogenic systemic fibrosis. , 2008, Magnetic resonance imaging clinics of North America.

[22]  J. Babb,et al.  Diffusion‐weighted imaging of the abdomen at 3.0 Tesla: Image quality and apparent diffusion coefficient reproducibility compared with 1.5 Tesla , 2011, Journal of magnetic resonance imaging : JMRI.

[23]  R. Badawi,et al.  Semiautomated segmentation for volumetric analysis of intratumoral ethiodol uptake and subsequent tumor necrosis after chemoembolization. , 2010, AJR. American journal of roentgenology.

[24]  D. Bluemke,et al.  Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. , 2003, AJR. American journal of roentgenology.

[25]  K. Jhaveri,et al.  CT and MRI of hepatocellular carcinoma: an update , 2010, Expert review of anticancer therapy.

[26]  Benjamin M Yeh,et al.  Parallel imaging and diffusion tensor imaging for diffusion-weighted MRI of the liver: preliminary experience in healthy volunteers. , 2004, AJR. American journal of roentgenology.

[27]  T. Murakami,et al.  Diffusion-weighted single-shot echoplanar MR imaging for liver disease. , 1999, AJR. American journal of roentgenology.

[28]  M Takahashi,et al.  Focal liver masses: characterization with diffusion-weighted echo-planar MR imaging. , 1997, Radiology.

[29]  J. M. Taylor,et al.  Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. , 2000, Journal of the National Cancer Institute.

[30]  D. Amadori,et al.  Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  T. Ichikawa,et al.  Diffusion-weighted MR imaging with a single-shot echoplanar sequence: detection and characterization of focal hepatic lesions. , 1998, AJR. American journal of roentgenology.

[32]  R. Lencioni,et al.  Treatment before Liver Transplantation for HCC , 2008, Annals of Surgical Oncology.

[33]  E. Hecht,et al.  Hepatocellular carcinoma: Assessment of response to transarterial chemoembolization with image subtraction , 2010, Journal of magnetic resonance imaging : JMRI.

[34]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[35]  Andrew C Larson,et al.  Diffusion‐weighted PROPELLER MRI for quantitative assessment of liver tumor necrotic fraction and viable tumor volume in VX2 rabbits , 2008, Journal of magnetic resonance imaging : JMRI.

[36]  J. Bruix,et al.  Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival , 2003, Hepatology.

[37]  A. Vignaud,et al.  The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study , 2011, European Radiology.

[38]  G. Morana,et al.  Optimal imaging of focal liver lesions , 2010 .

[39]  Jean-Luc Daire,et al.  Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients. , 2003, Radiology.

[40]  J. Geschwind,et al.  Chemoembolization of liver tumor in a rabbit model: assessment of tumor cell death with diffusion-weighted MR imaging and histologic analysis. , 2000, Journal of vascular and interventional radiology : JVIR.

[41]  Y. Ni,et al.  Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging. , 2005, Radiology.

[42]  Roman Rouzier,et al.  Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response , 2004, Cancer.

[43]  Jian Xu,et al.  Diffusion‐weighted imaging of the liver: Comparison of navigator triggered and breathhold acquisitions , 2009, Journal of magnetic resonance imaging : JMRI.

[44]  Bachir Taouli,et al.  Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. , 2010, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[45]  A. Zhu.  Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma , 2008, Cancer.

[46]  L. Mariani,et al.  Radiofrequency Ablation of Small Hepatocellular Carcinoma in Cirrhotic Patients Awaiting Liver Transplantation: A Prospective Study , 2004, Annals of surgery.

[47]  Olav Haraldseth,et al.  Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging , 2000, Magnetic resonance in medicine.

[48]  D. Bluemke,et al.  The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. , 2006, Journal of vascular and interventional radiology : JVIR.

[49]  J. Babb,et al.  T1 hyperintense renal lesions: characterization with diffusion-weighted MR imaging versus contrast-enhanced MR imaging. , 2009, Radiology.

[50]  S. Luk,et al.  Diffusion-weighted MR imaging of the liver: distinguishing hepatic abscess from cystic or necrotic tumor , 2001, Abdominal Imaging.

[51]  J. Bruix,et al.  Prognostic prediction and treatment strategy in hepatocellular carcinoma , 2002, Hepatology.

[52]  D. Bluemke,et al.  Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. , 2007, Journal of vascular and interventional radiology : JVIR.

[53]  D. Le Bihan,et al.  Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. , 1988, Radiology.

[54]  J. McGahan,et al.  Hepatic ablation with use of radio-frequency electrocautery in the animal model. , 1992, Journal of vascular and interventional radiology : JVIR.

[55]  F. Miller,et al.  Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization. , 2006, Journal of vascular and interventional radiology : JVIR.

[56]  Mathias Langer,et al.  Osteosarcoma: Preliminary Results of In Vivo Assessment of Tumor Necrosis After Chemotherapy With Diffusion- and Perfusion-Weighted Magnetic Resonance Imaging , 2006, Investigative radiology.

[57]  Larissa Braga,et al.  Hepatic tumor response evaluation by MRI , 2011, NMR in biomedicine.

[58]  H. El‐Serag,et al.  Hepatocellular carcinoma: recent trends in the United States. , 2004, Gastroenterology.

[59]  E. Hecht,et al.  Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. , 2008, Radiology.

[60]  M. Wendland,et al.  Osteogenic sarcoma: noninvasive in vivo assessment of tumor necrosis with diffusion-weighted MR imaging. , 1998, Radiology.

[61]  Toshinori Hirai,et al.  Usefulness of diffusion‐weighted MRI with echo‐planar technique in the evaluation of cellularity in gliomas , 1999, Journal of magnetic resonance imaging : JMRI.

[62]  A. Herneth,et al.  Apparent diffusion coefficient: a quantitative parameter for in vivo tumor characterization. , 2003, European journal of radiology.

[63]  A. Karantanas,et al.  Respiratory gated diffusion-weighted imaging of the liver: value of apparent diffusion coefficient measurements in the differentiation between most commonly encountered benign and malignant focal liver lesions , 2008, European Radiology.

[64]  John Wong,et al.  Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma , 2002, Hepatology.